Status:
COMPLETED
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Lead Sponsor:
Bayer
Conditions:
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Eligibility:
All Genders
18+ years
Brief Summary
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate canc...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Adult patients with documented diagnosis of mCRPC (≥18 years at diagnosis), and
- Received Ra-223 as one of the therapies between Jan 1, 2013 and Jun 31, 2019 after diagnosis of mCRPC
- Exclusion criteria
- \- Patients involved in clinical trials
Exclusion
Key Trial Info
Start Date :
August 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
1180 Patients enrolled
Trial Details
Trial ID
NCT04516161
Start Date
August 3 2020
End Date
March 31 2021
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer Flatiron Xofigo Registry database
Whippany, New Jersey, United States, 07981